Global Hepatitis B and C Diagnostics Market 2016-2020
About Hepatitis B and Hepatitis C
Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
Technavio’s analysts forecast the global hepatitis B and C diagnostics market to grow at a CAGR of 6.35% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatitis B and C diagnostics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of immunodiagnostics and nucleic acid test (NAT) instruments and consumables to hospitals, diagnostic centers, and research institutes.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hepatitis B and C Diagnostics Market 2016-2020
Technavio recognizes the following companies as the key players in the global hepatitis B and C diagnostics market: Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare, and QIAGEN.
Other Prominent Vendors in the market are: Affymetrix, Allele Biotechnology, Axis-Shield, Becton Dickinson, bioMérieux, Cepheid¸ Chembio Diagnostics, DiaMetra, DiaSorin, Enzo Life Sciences, Hologic, ImmunoDX, MedMira, OraSure Technologies, Quest Diagnostics, Quidel, Randox Laboratories, Vela Diagnostics, Vital Diagnostics, and ZEUS Scientific.
Commenting on the report, an analyst from Technavio’s team said: “One of the key trends for market growth will be high demand for biomarker-based tests. Sophisticated R&D for proteomics, nucleic acid expression, and genome sequencing has led to the emergence of molecular biomarkers. Biomarkers are proteins, genes, hormones, and other molecular entities that detect the absence or presence of a disease. Technological advancements are driving manufacturers to develop assays that identify biomarkers in high-growth clinical areas such as infectious diseases, including hepatitis and retroviruses. Biomarker-based tests will likely replace conventional drug therapeutics and account for increased revenue and sales from personalized test devices. To better reach the market, companies are developing cost-effective biomarker-based tests. Increased approvals for devices and rise in product launches are expected to propel market growth during the forecast period.”
According to the report, increase in demand for automation and system integration will be a key driver for market growth. An increasing number of consumers are opting for fully automated and semi-automated systems over conventional (manual) systems. Laboratory automation increases productivity, with high test volumes handled efficiently by few people. This type of automation helps when there is a shortage of trained technicians. Also, automated systems provide precise results, which are otherwise difficult to achieve. Vendors are developing devices and systems that help integrate laboratory applications. For instance, the COBAS 6000 modular platform by Roche Diagnostics offers optimum efficiency and consolidation in medium- and high-volume laboratories. The company estimates that 95% of the workload is consolidated into this system, which allows for an upgrade in workload. The system's software and graphical user interface (GUI) permit streamlined information management and offer solutions ranging from remote test ordering to sophisticated result analysis. Integrated systems with enhanced automation and efficiency are expected to fuel market growth during the forecast period.
Further, the report states that one of the challenges for the market will be regulatory and reimbursement hurdles that limit the adoption rate. Validation studies and guidelines help companies to register their diagnostic testing devices and assays with regulatory authorities. The process, however, is time-consuming, requiring documentation at every stage and real-time data collection. The studies require real-time sample collections or samples from biobanks. For infectious diseases such as hepatitis B and C infections, the lack of such sample storage facilities makes validation studies difficult for manufacturers. Also, there is no clarity on the reimbursements for diagnostic devices globally. To reduce costs, countries such as the US, Australia, and few countries in EU are decreasing the reimbursement amount for diagnostic testing devices. These factors restrain market growth. The lack of reimbursement or insufficient reimbursement severely hinders the adoption of these devices, especially in developed countries.
Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare, QIAGEN, Affymetrix, Allele Biotechnology, Axis-Shield, Becton Dickinson, bioMérieux, Cepheid¸ Chembio Diagnostics, DiaMetra, DiaSorin, Enzo Life Sciences, Hologic, ImmunoDX, MedMira, OraSure Technologies, Quest Diagnostics, Quidel, Randox Laboratories, Vela Diagnostics, Vital Diagnostics, ZEUS Scientific.